Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 13 | 2024 | 491 | 2.160 |
Why?
|
| Brain Neoplasms | 16 | 2024 | 1217 | 1.800 |
Why?
|
| Brain Stem Neoplasms | 7 | 2023 | 39 | 1.740 |
Why?
|
| Medulloblastoma | 8 | 2021 | 338 | 0.810 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2024 | 194 | 0.790 |
Why?
|
| Antineoplastic Agents | 7 | 2023 | 1677 | 0.750 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2023 | 876 | 0.640 |
Why?
|
| Polycomb Repressive Complex 1 | 2 | 2014 | 29 | 0.590 |
Why?
|
| Cerebellar Neoplasms | 5 | 2021 | 282 | 0.580 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2023 | 520 | 0.550 |
Why?
|
| Antigens, CD | 2 | 2014 | 420 | 0.480 |
Why?
|
| Glycoproteins | 2 | 2014 | 369 | 0.470 |
Why?
|
| Pyrimidines | 3 | 2023 | 374 | 0.450 |
Why?
|
| Peptides | 2 | 2014 | 796 | 0.430 |
Why?
|
| Glioblastoma | 3 | 2023 | 333 | 0.430 |
Why?
|
| Chemoradiotherapy | 5 | 2021 | 101 | 0.430 |
Why?
|
| Down-Regulation | 1 | 2014 | 697 | 0.400 |
Why?
|
| Oncolytic Viruses | 3 | 2023 | 71 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 1229 | 0.390 |
Why?
|
| Oncolytic Virotherapy | 3 | 2023 | 83 | 0.380 |
Why?
|
| AC133 Antigen | 3 | 2024 | 35 | 0.370 |
Why?
|
| Neoplastic Stem Cells | 4 | 2024 | 294 | 0.370 |
Why?
|
| Benzimidazoles | 3 | 2020 | 128 | 0.360 |
Why?
|
| Mice, SCID | 12 | 2023 | 571 | 0.350 |
Why?
|
| Child | 29 | 2024 | 24208 | 0.340 |
Why?
|
| Wilms Tumor | 2 | 2019 | 112 | 0.330 |
Why?
|
| von Willebrand Diseases | 1 | 2009 | 50 | 0.310 |
Why?
|
| Neuroimaging | 2 | 2020 | 332 | 0.280 |
Why?
|
| Disease Models, Animal | 9 | 2023 | 4267 | 0.270 |
Why?
|
| Ependymoma | 2 | 2022 | 133 | 0.260 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 602 | 0.240 |
Why?
|
| Piperazines | 2 | 2021 | 231 | 0.240 |
Why?
|
| CD57 Antigens | 1 | 2024 | 5 | 0.240 |
Why?
|
| Fireflies | 1 | 2023 | 2 | 0.230 |
Why?
|
| Gangliosides | 1 | 2024 | 64 | 0.220 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2023 | 23 | 0.220 |
Why?
|
| Cell Line, Tumor | 9 | 2023 | 3279 | 0.220 |
Why?
|
| Neoplasm Grading | 5 | 2024 | 267 | 0.210 |
Why?
|
| Rhabdoid Tumor | 1 | 2023 | 49 | 0.210 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 1431 | 0.210 |
Why?
|
| Humans | 38 | 2024 | 123180 | 0.210 |
Why?
|
| Mice | 14 | 2024 | 17486 | 0.210 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2019 | 804 | 0.200 |
Why?
|
| Animals | 20 | 2024 | 33728 | 0.200 |
Why?
|
| Symporters | 1 | 2022 | 66 | 0.200 |
Why?
|
| Aurora Kinase A | 2 | 2023 | 40 | 0.200 |
Why?
|
| Neutropenia | 1 | 2023 | 202 | 0.200 |
Why?
|
| Azepines | 2 | 2023 | 61 | 0.200 |
Why?
|
| Child, Preschool | 13 | 2024 | 13862 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 229 | 0.190 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2021 | 57 | 0.190 |
Why?
|
| Optic Nerve Glioma | 1 | 2021 | 21 | 0.180 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 368 | 0.180 |
Why?
|
| Craniospinal Irradiation | 1 | 2021 | 58 | 0.180 |
Why?
|
| Gadolinium | 1 | 2021 | 103 | 0.180 |
Why?
|
| Mice, Inbred NOD | 4 | 2023 | 285 | 0.180 |
Why?
|
| Thalidomide | 1 | 2020 | 36 | 0.180 |
Why?
|
| Transplantation, Heterologous | 4 | 2014 | 254 | 0.180 |
Why?
|
| Endpoint Determination | 1 | 2020 | 53 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1873 | 0.170 |
Why?
|
| Proton Therapy | 1 | 2021 | 120 | 0.170 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 42 | 0.170 |
Why?
|
| Pyridines | 1 | 2021 | 223 | 0.160 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 287 | 0.160 |
Why?
|
| Drug Repositioning | 1 | 2018 | 22 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 571 | 0.160 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 105 | 0.160 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 469 | 0.160 |
Why?
|
| Digoxin | 1 | 2018 | 41 | 0.150 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 208 | 0.150 |
Why?
|
| Systems Biology | 1 | 2018 | 58 | 0.150 |
Why?
|
| Capecitabine | 1 | 2017 | 17 | 0.150 |
Why?
|
| Adolescent | 13 | 2024 | 19087 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2020 | 313 | 0.140 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1683 | 0.140 |
Why?
|
| Survival Analysis | 5 | 2020 | 1470 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 254 | 0.140 |
Why?
|
| Male | 20 | 2024 | 60022 | 0.140 |
Why?
|
| Germinoma | 1 | 2016 | 31 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 53 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 217 | 0.130 |
Why?
|
| Female | 19 | 2024 | 65428 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 715 | 0.120 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2014 | 19 | 0.120 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2014 | 41 | 0.120 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2014 | 22 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 37 | 0.120 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 141 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 831 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 1117 | 0.120 |
Why?
|
| Young Adult | 7 | 2024 | 8870 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 3518 | 0.120 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 151 | 0.110 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2014 | 52 | 0.110 |
Why?
|
| Supratentorial Neoplasms | 1 | 2014 | 37 | 0.110 |
Why?
|
| Picornaviridae | 1 | 2013 | 20 | 0.110 |
Why?
|
| Mice, Nude | 1 | 2014 | 692 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2017 | 671 | 0.110 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2014 | 124 | 0.110 |
Why?
|
| Cell Adhesion | 1 | 2014 | 321 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 665 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 353 | 0.100 |
Why?
|
| Radiotherapy Dosage | 2 | 2021 | 185 | 0.090 |
Why?
|
| Infant | 5 | 2024 | 12323 | 0.090 |
Why?
|
| Thiourea | 1 | 2010 | 9 | 0.090 |
Why?
|
| Half-Life | 1 | 2010 | 156 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2023 | 164 | 0.090 |
Why?
|
| Disease Progression | 3 | 2021 | 2024 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2010 | 313 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 191 | 0.080 |
Why?
|
| Macaca mulatta | 1 | 2010 | 494 | 0.080 |
Why?
|
| Apoptosis | 4 | 2018 | 1782 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 227 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1267 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1240 | 0.070 |
Why?
|
| Recurrence | 2 | 2022 | 1420 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2307 | 0.070 |
Why?
|
| Prognosis | 3 | 2021 | 4508 | 0.070 |
Why?
|
| Kinetics | 1 | 2009 | 1313 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 5048 | 0.070 |
Why?
|
| Models, Biological | 1 | 2010 | 1442 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 1062 | 0.060 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.060 |
Why?
|
| Cell Movement | 2 | 2021 | 831 | 0.060 |
Why?
|
| Pons | 1 | 2023 | 32 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2023 | 15981 | 0.050 |
Why?
|
| Mutation | 3 | 2023 | 5774 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1684 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 252 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 56 | 0.050 |
Why?
|
| Dissection | 1 | 2021 | 52 | 0.050 |
Why?
|
| Morpholines | 1 | 2021 | 56 | 0.050 |
Why?
|
| Brain | 3 | 2021 | 2947 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 150 | 0.050 |
Why?
|
| Benzamides | 1 | 2021 | 107 | 0.050 |
Why?
|
| Survival Rate | 2 | 2020 | 1995 | 0.050 |
Why?
|
| Protons | 1 | 2021 | 91 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2043 | 0.050 |
Why?
|
| Everolimus | 1 | 2021 | 46 | 0.050 |
Why?
|
| Patient-Specific Modeling | 1 | 2020 | 7 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 38 | 0.050 |
Why?
|
| Dactinomycin | 1 | 2020 | 67 | 0.050 |
Why?
|
| Serial Passage | 1 | 2020 | 19 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 54 | 0.050 |
Why?
|
| Pyridones | 1 | 2021 | 112 | 0.050 |
Why?
|
| Purines | 1 | 2021 | 107 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 53 | 0.040 |
Why?
|
| Cisplatin | 1 | 2021 | 242 | 0.040 |
Why?
|
| Perfusion Imaging | 1 | 2020 | 11 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 81 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 96 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2020 | 63 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1239 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 158 | 0.040 |
Why?
|
| Mercaptopurine | 1 | 2019 | 71 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 229 | 0.040 |
Why?
|
| Adult | 4 | 2021 | 29039 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2021 | 193 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2020 | 165 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2021 | 210 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 132 | 0.040 |
Why?
|
| Allopurinol | 1 | 2019 | 70 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2018 | 42 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 73 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 113 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 581 | 0.040 |
Why?
|
| Neurofibromatosis 1 | 1 | 2019 | 59 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 222 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 1294 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 804 | 0.040 |
Why?
|
| Tablets | 1 | 2017 | 28 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 667 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 469 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2018 | 330 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1216 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 516 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2019 | 200 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2019 | 257 | 0.030 |
Why?
|
| Craniotomy | 1 | 2017 | 107 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 2599 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1683 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2021 | 806 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2022 | 991 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 179 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 803 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1088 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2820 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2021 | 12103 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 2108 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2019 | 509 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 2801 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 680 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2014 | 155 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 649 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 27 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1597 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 225 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 966 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2012 | 101 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 1477 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 262 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2014 | 991 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6201 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 514 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1760 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 2943 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 1013 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1102 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 3049 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2008 | 82 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 300 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6028 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 4500 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 4346 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 2048 | 0.010 |
Why?
|